CSBio CSBio

X
[{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma Announces \u20ac18 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MaaT Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$21.4 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of Cgvhd","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at EBMT 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MaaT Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$29.5 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma Announces Series B Extension and Final Closing with Total of \u20ac25 Million ($29.5 Million)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MaaT Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medsenic Partners With Phebra for the Clinical Development of the Oral Form of Arscimed\u00ae for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Medsenic"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data Reinforcing Promising Safety and Efficacy Profile of Brain-Penetrant Tolebrutinib Presented at ECTRIMS 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Medsenic"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall Survival in Patients Undergoing Hematopoietic Stem Cell Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"MaaT Pharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"MaaT Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: Phase 2 Results Demonstrate Rilzabrutinib Rapidly Reduced Itch Severity and Significantly Improved Disease Activity in Adults with Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            PRN1008 (rilzabrutinib) is an oral, reversible covalent BTK inhibitor. It is being evaluated for the treatment of adults with moderate-to-severe chronic spontaneous urticaria.

            Lead Product(s): Rilzabrutinib

            Therapeutic Area: Immunology Product Name: PRN1008

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2024

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Tolebrutinib is an investigational brain-penetrant Bruton’s tyrosine kinase inhibitor that achieves CSF concentrations needed for targeting B lymphocytes and microglial cells, modulating neuroinflammation.

            Lead Product(s): Tolebrutinib

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2).

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: KD025-209

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 01, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            In a notice received from the FDA on March 9, 2021, the Company was informed that the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of belumosudil has been extended to August, 2021.

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: KD025

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 11, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Kadmon plans to use a part of the proceeds to prepare to commercialize belumosudil for chronic graft-vs-host disease in the U.S; for its clinical-stage product candidates; for discovery and preclinical studies of other product candidates; and for general corporate purposes.

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: KD025

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co

            Deal Size: $240.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 16, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            The presentation will include 12-month efficacy and safety data and key secondary endpoints including duration of response, Failure-Free Survival, steroid dose reductions and quality-of-life improvements.

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: KD025

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD who failed two or more lines of systemic therapy.

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: KD025

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            The multicenter Phase 2A trial is anticipated to enroll approximately 25 patients with active IgG4-RD in two arms, rilzabrutinib with glucocorticoids or glucocorticoids only.

            Lead Product(s): Rilzabrutinib

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Belumosudil is being studied in an ongoing double-blind, placebo-controlled Phase 2 clinical trial in adults with SSc. The study is enrolling 60 patients to receive belumosudil 200 mg QD, belumosudil 200 mg BID or placebo for 24 weeks.

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: KD025

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            The proceeds from the offering will be used to advance belumosudil toward a NDA filing with the U.S FDA and support related pre-commercialization activities and provide additional working capital for general corporate purposes.

            Lead Product(s): Belumosudil

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 05, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY